[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621705":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":36,"responsibleParty":51,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":70,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Umeå University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Antibiotic treatment",null,"Participants with Clostridioides difficile infection receiving standard antibiotic treatment as part of routine clinical care.",[13],"Other: Antibiotic treatment",{"label":15,"type":10,"description":16,"interventionNames":17},"Fecal microbiota transplantation (FMT)","Participants with Clostridioides difficile infection receiving fecal microbiota transplantation as part of routine clinical care.",[18],"Other: Fecal microbiota transplantation (FMT)",[20,23],{"type":6,"name":9,"description":21,"armGroupLabels":22,"otherNames":10},"Standard antibiotic treatment for Clostridioides difficile infection administered as part of routine clinical care, according to clinical guidelines. Treatment selection and duration are determined by the treating physician.",[9],{"type":6,"name":15,"description":24,"armGroupLabels":25,"otherNames":10},"Fecal microbiota transplantation administered as part of routine clinical care for Clostridioides difficile infection. The route of administration is determined by clinical practice and physician decision.",[15],[27],{"name":28,"affiliation":29,"role":30},"Johan Rasmuson, MD, PhD","Umeå University, Department of Clinical Microbiology and Umeå University Hospital, Department of Infectious Diseases","PRINCIPAL_INVESTIGATOR",[32],{"name":28,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","0046-907850000","johan.rasmuson@umu.se",[37],{"facility":38,"status":39,"city":40,"state":10,"zip":10,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Umeå University Hospital","RECRUITING","Umeå","Sweden","SE",{"type":44,"coordinates":45},"Point",[46,47],20.25972,63.82842,{"lat":47,"lon":46},[50],{"name":28,"role":33,"phone":34,"phoneExt":10,"email":35},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[54],{"name":55,"class":56},"Region Västerbotten","OTHER_GOV","100621705","clostridioides-difficile-understanding-responses-and-treatment-effects-100621705",false,"NCT07374094","Clostridioides Difficile: Understanding Responses and Treatment Effects","Studies of Treatment Effects, Host-Pathogen Responses, and Therapeutic Mechanisms in Clostridioides Difficile Infection","CURE-CDI","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Symptomatic, microbiologically verified Clostridioides difficile infection\n* Receiving inpatient or outpatient care at Umeå University Hospital\n* Able and willing to provide written informed consent\n* Willing to participate in protocol-driven follow-up for up to 5 years\n\nExclusion Criteria:\n\n* Age below 18 years\n* Inability to provide written informed consent","ALL","18 Years",{"count":68,"type":69},200,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to learn how different treatments for Clostridioides difficile infection (CDI) work, and which biological mechanisms are involved in recovery. The study will compare standard antibiotic treatment and fecal microbiota transplantation (FMT).\n\nThe main questions it aims to answer are:\n\n* How do antibiotic treatment and FMT affect treatment outcome in CDI?\n* How does the gut microbiota change during and after treatment?\n* Which microbial and metabolic factors are associated with recovery or treatment failure?\n* How does treatment affect the intestinal barrier, immune response, and patient-reported quality of life?\n\nParticipants with CDI will receive treatment as part of routine clinical care, either antibiotics or FMT. Researchers will follow participants over time and collect biological samples to study treatment effects.\n\nParticipants will:\n\n* Provide stool samples during the acute infection and during follow-up\n* Have treatment outcomes assessed at 2 and 8 weeks\n* Be followed for up to 5 years to study long-term effects\n* Provide blood and urine samples during follow-up\n* Provide nasal samples to study potential microbiota changes at distant body sites\n* Complete questionnaires on symptoms and health-related quality of life\n* In a subgroup, undergo repeated sigmoid biopsies to study intestinal mucosal healing\n\nThe results are expected to increase understanding of how FMT and antibiotics lead to recovery in CDI and may support improved and more targeted future treatments.",[74],"Clostridioides Difficile Infection",[76,77,78,79,80,81,82,83,84,9,85],"Clostridioides difficile infection","Recurrent Clostridioides difficile infection","Fecal microbiota transplantation","Gut microbiota","Microbiome engraftment","Dysbiosis","Microbial metabolites","Intestinal barrier","Immune response","Observational study","2026-01-20",{"date":88,"type":89},"2026-01-28","ACTUAL",{"date":91,"type":69},"2026-01-26",{"date":93,"type":69},"2045-12",{"name":5,"class":6},1]